Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study

Abstract Background Hepatitis C is curable with direct-acting antivirals (DAAs). However, treatment uptake remains low among marginalized populations such as people who inject drugs. We sought to understand challenges to treatment uptake with DAAs among people living with hepatitis C and compare tre...

Full description

Bibliographic Details
Main Authors: Tony Antoniou, Cheryl Pritlove, Dana Shearer, Mina Tadrous, Hemant Shah, Tara Gomes
Format: Article
Language:English
Published: BMC 2023-06-01
Series:International Journal for Equity in Health
Subjects:
Online Access:https://doi.org/10.1186/s12939-023-01924-4
_version_ 1827723969452572672
author Tony Antoniou
Cheryl Pritlove
Dana Shearer
Mina Tadrous
Hemant Shah
Tara Gomes
author_facet Tony Antoniou
Cheryl Pritlove
Dana Shearer
Mina Tadrous
Hemant Shah
Tara Gomes
author_sort Tony Antoniou
collection DOAJ
description Abstract Background Hepatitis C is curable with direct-acting antivirals (DAAs). However, treatment uptake remains low among marginalized populations such as people who inject drugs. We sought to understand challenges to treatment uptake with DAAs among people living with hepatitis C and compare treatment experiences between people who do and do not inject prescription and/or unregulated drugs. Methods We conducted a qualitative study using focus groups with 23 adults aged 18 years and over who completed DAA treatment or were about to begin such treatment at the time of the study. Participants were recruited from hepatitis C treatment clinics across Toronto, Ontario. We drew upon stigma theory to interpret participants’ accounts. Results Following analysis and interpretation, we generated five theoretically-informed themes characterizing the experiences of individuals accessing DAAs: “being ‘worthy’ of the cure”, “spatially enacted stigma”, “countering social and structural vulnerability: the importance of peers”, “identity disruption and contagion: attaining a ‘social cure’” and “challenging stigma with population-based screening”. Overall, our findings suggest that structural stigma generated and reproduced through healthcare encounters limits access to DAAs among people who inject drugs. Peer-based programs and population-based screening were proposed by participants as mechanisms for countering stigma within health care settings and ‘normalizing’ hepatitis C among the general population. Conclusions Despite the availability of curative therapies, access to such treatment for people who inject drugs is limited by stigma enacted in and structured within healthcare encounters. Developing novel, low-threshold delivery programs that remove power differentials and attend to the social and structural determinants of health and reinfection are needed to facilitate further scale up of DAAs and support the goal of eradicating hepatitis C as a public health threat.
first_indexed 2024-03-10T22:08:18Z
format Article
id doaj.art-47f77def6c834319a3374c5bb12d51f0
institution Directory Open Access Journal
issn 1475-9276
language English
last_indexed 2024-03-10T22:08:18Z
publishDate 2023-06-01
publisher BMC
record_format Article
series International Journal for Equity in Health
spelling doaj.art-47f77def6c834319a3374c5bb12d51f02023-11-19T12:44:19ZengBMCInternational Journal for Equity in Health1475-92762023-06-0122111310.1186/s12939-023-01924-4Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative studyTony Antoniou0Cheryl Pritlove1Dana Shearer2Mina Tadrous3Hemant Shah4Tara Gomes5Li Ka Shing Knowledge Institute, Unity HealthLi Ka Shing Knowledge Institute, Unity HealthLi Ka Shing Knowledge Institute, Unity HealthLeslie Dan Faculty of Pharmacy, University of TorontoToronto Centre for Liver Disease, University Health NetworkLi Ka Shing Knowledge Institute, Unity HealthAbstract Background Hepatitis C is curable with direct-acting antivirals (DAAs). However, treatment uptake remains low among marginalized populations such as people who inject drugs. We sought to understand challenges to treatment uptake with DAAs among people living with hepatitis C and compare treatment experiences between people who do and do not inject prescription and/or unregulated drugs. Methods We conducted a qualitative study using focus groups with 23 adults aged 18 years and over who completed DAA treatment or were about to begin such treatment at the time of the study. Participants were recruited from hepatitis C treatment clinics across Toronto, Ontario. We drew upon stigma theory to interpret participants’ accounts. Results Following analysis and interpretation, we generated five theoretically-informed themes characterizing the experiences of individuals accessing DAAs: “being ‘worthy’ of the cure”, “spatially enacted stigma”, “countering social and structural vulnerability: the importance of peers”, “identity disruption and contagion: attaining a ‘social cure’” and “challenging stigma with population-based screening”. Overall, our findings suggest that structural stigma generated and reproduced through healthcare encounters limits access to DAAs among people who inject drugs. Peer-based programs and population-based screening were proposed by participants as mechanisms for countering stigma within health care settings and ‘normalizing’ hepatitis C among the general population. Conclusions Despite the availability of curative therapies, access to such treatment for people who inject drugs is limited by stigma enacted in and structured within healthcare encounters. Developing novel, low-threshold delivery programs that remove power differentials and attend to the social and structural determinants of health and reinfection are needed to facilitate further scale up of DAAs and support the goal of eradicating hepatitis C as a public health threat.https://doi.org/10.1186/s12939-023-01924-4Direct acting antiviralsHepatitis CPeople who inject drugsQualitative research
spellingShingle Tony Antoniou
Cheryl Pritlove
Dana Shearer
Mina Tadrous
Hemant Shah
Tara Gomes
Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
International Journal for Equity in Health
Direct acting antivirals
Hepatitis C
People who inject drugs
Qualitative research
title Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
title_full Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
title_fullStr Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
title_full_unstemmed Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
title_short Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
title_sort accessing hepatitis c direct acting antivirals among people living with hepatitis c a qualitative study
topic Direct acting antivirals
Hepatitis C
People who inject drugs
Qualitative research
url https://doi.org/10.1186/s12939-023-01924-4
work_keys_str_mv AT tonyantoniou accessinghepatitiscdirectactingantiviralsamongpeoplelivingwithhepatitiscaqualitativestudy
AT cherylpritlove accessinghepatitiscdirectactingantiviralsamongpeoplelivingwithhepatitiscaqualitativestudy
AT danashearer accessinghepatitiscdirectactingantiviralsamongpeoplelivingwithhepatitiscaqualitativestudy
AT minatadrous accessinghepatitiscdirectactingantiviralsamongpeoplelivingwithhepatitiscaqualitativestudy
AT hemantshah accessinghepatitiscdirectactingantiviralsamongpeoplelivingwithhepatitiscaqualitativestudy
AT taragomes accessinghepatitiscdirectactingantiviralsamongpeoplelivingwithhepatitiscaqualitativestudy